The Case Western Reserve University AIDS Clinical Trials Unit serves a 5.4 million population region that accounts for 47% of Ohio's AIDS cases. This section provides rationale for the continuation of an established ACTU that is a vital community resource and is an important contributor to the national ACTG effort. This Cleveland and Toledo-based ACTU has a strong record of cost efficient accrual of patients including underserved minorities into ACTG trials. To provide additional trials access to minority populations, a second ACTU subunit will be established at MetroHealth Medical Center, a county hospital on Cleveland's West Side that serves large African-American and Hispanic communities. The main ACTU and its two subunits are the three largest HIV care providers in Northern Ohio and each provides care without regard to ability to pay. As both HIV care providers and AIDS researchers, these units integrate clinical care and clinical research and their staff have earned the trust and confidence of their patients and communities. Outreach to populations currently under-represented in ACTG trials is a major component of ACTU activities. These Units project a minimum accrual of 140 patients per year to ACTG trials.

Project Start
1997-01-01
Project End
1997-12-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
10
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Chang, J Judy; Woods, Matt; Lindsay, Robert J et al. (2013) Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J Infect Dis 208:830-8
Kyeyune, Fred; Nankya, Immaculate; Metha, Samar et al. (2013) Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. AIDS 27:1899-909
Imamichi, Hiromi; Degray, Gerald; Asmuth, David M et al. (2011) HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS 25:159-64
Anthony, D D; Umbleja, T; Aberg, J A et al. (2011) Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals. Vaccine 29:3558-63
Tebit, Denis M; Lobritz, Michael; Lalonde, Matthew et al. (2010) Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol 84:9817-30
Lok, Judith J; Bosch, Ronald J; Benson, Constance A et al. (2010) Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS 24:1867-76
Kalayjian, Robert C (2010) The treatment of HIV-associated nephropathy. Adv Chronic Kidney Dis 17:59-71
Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Sereti, Irini; Dunham, Richard M; Spritzler, John et al. (2009) IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 113:6304-14

Showing the most recent 10 out of 116 publications